Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.
Strietz J, Stepputtis SS, Preca BT, Vannier C, Kim MM, Castro DJ, Au Q, Boerries M, Busch H, Aza-Blanc P, Heynen-Genel S, Bronsert P, Kuster B, Stickeler E, Brabletz T, Oshima RG, Maurer J. Strietz J, et al. Among authors: vannier c. Oncotarget. 2016 Dec 13;7(50):83278-83293. doi: 10.18632/oncotarget.13086. Oncotarget. 2016. PMID: 27829216 Free PMC article.
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.
Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. Wellner U, et al. Among authors: vannier c. Nat Cell Biol. 2009 Dec;11(12):1487-95. doi: 10.1038/ncb1998. Epub 2009 Nov 22. Nat Cell Biol. 2009. PMID: 19935649
Bind or bleed.
Huttner W, Niehrs C, Vannier C. Huttner W, et al. Among authors: vannier c. Curr Biol. 1991 Oct;1(5):309-10. doi: 10.1016/0960-9822(91)90094-d. Curr Biol. 1991. PMID: 15336107 No abstract available.
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
Dechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Söling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K. Dechow T, et al. Among authors: vannier c. Eur J Haematol. 2022 Feb;108(2):133-144. doi: 10.1111/ejh.13719. Epub 2021 Nov 15. Eur J Haematol. 2022. PMID: 34714555 Free PMC article.
80 results